Yuanyuan Zhang

Articles by Yuanyuan Zhang

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

ByErika P. Hamilton, MD,Rinath M. Jeselsohn,Sara A. Hurvitz, MD,Dejan Juric,Hyo S Han,Melinda L. Telli, MD,George Zahrah,Rita Nanda, MD,Yuanyuan Zhang,Weiwei Tan,Elizabeth Duperret,Eric Zhi,Cecile Mather,Anne F. Schott, MD

August 10th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer

FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer

Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma

Personalized Vaccines May Have Utility Across All Lung Cancer Stages

Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma